MedPath

Memory Enhancement Using Transcranial Alternating Current Stimulation

Not Applicable
Recruiting
Conditions
Alzheimer Disease
Mild Cognitive Impairment
Interventions
Device: Gamma (40 Hz) tACS at the precuneus region
Device: Sham tACS at the precuneus region
Registration Number
NCT06202872
Lead Sponsor
Amsterdam UMC, location VUmc
Brief Summary

The 32 million Alzheimer's disease (AD) and 69 million prodromal AD patients worldwide contribute to a large economic burden. Effective and safe therapies that slow or prevent the progression from mild cognitive impairment (MCI) to AD are therefore of high priority. Transcranial alternating current stimulation (tACS) is a safe and patient-friendly non-invasive brain stimulation technique that serves as a potential candidate for reducing and/or slowing cognitive impairment. Application of tACS in the gamma frequency range, specifically around 40 Hz, has been studied in patients with AD and MCI due to AD. In these patients, a single session of 40 Hz tACS at the precuneus showed to improve episodic memory and to increase gamma power, as measured with electroencephalography. These findings will be replicated in the current study in patients with MCI due to AD, using magnetoencephalography (MEG) recorded before, during and after tACS. In this way, brain activity and network changes that underlie this improvement in episodic memory can be studied with greater temporal and spatial detail.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
27
Inclusion Criteria
  • Recent (not more than 6 months ago) amnestic MCI diagnosis, which consensus is obtained in a multidisciplinary meeting after an extended multidisciplinary test battery at the memory clinic, including confirmation of AD pathology with cerebrospinal fluid biomarkers: abnormal p-tau/Aβ42 ratio of > 0.023
Exclusion Criteria
  • Suffering from serious neurological, psychiatric or somatic comorbidity
  • Suffering from epileptic seizures or severe claustrophobia
  • Intensive use of psychoactive medication
  • Having a cardiac pacemaker, internal cardiac defibrillator or other intracorporeal device that interferes with MEG recordings

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Active tACSGamma (40 Hz) tACS at the precuneus regionGamma (40 Hz) tACS at the precuneus region
Sham tACSSham tACS at the precuneus regionSham tACS at the precuneus region
Primary Outcome Measures
NameTimeMethod
Change in Rey Auditory Verbal Learning test scoresImmediately before and after intervention

The Rey Auditory Verbal Learning (RAVL) test evaluates verbal episodic memory and is designed as a list-learning paradigm in which the subject hears a list of 15 nouns. The participant is asked to recall as many words from the list as possible after each of 5 repetitions of free-recall (total recall), and 15 minutes after an interference trial (long delayed recall). Scores range from 0 to 75 (total recall) and 0 to 15 (long delayed recall), with higher scores meaning a better outcome. An increase in RAVL test (total and long delayed recall) after active but not sham tACS is expected.

Change in Face-Name Association Task scoresImmediately before and after intervention

The Face-Name Association Task assesses associative episodic memory and is a computer paradigm consisting of an encoding and a retrieval phase of face-name pairs. During the encoding phase, participants are instructed to remember a set of 12 faces and names they are paired. In two additional learning trials, participants are shown the previously learned faces and are asked to recall the correct name associated with each face (inital recognition). This recall of the correct name associated with a learned face is repeated 5 minutes after the learning trials during the retrieval phase (associative recognition). Scores range from 0 to 24 (inital recognition) and 0 to 12 (associative recognition), with higher scores meaning a better outcome. An increase in FNAT score (initial and associative recognition) after active but not sham tACS is expected.

Secondary Outcome Measures
NameTimeMethod
Change in functional connectivity source space resting-state MEG (PLI)Immediately before and after intervention

Change in phase lag index (PLI) will be used, expecting a decrease in PLI in theta band after active but not sham tACS.

Change in source space resting-state MEG network structure (clustering coefficient and path length)Immediately before and after intervention

Change in graph theory parameters will be used as a measure of global network structure. Preserved small-world configuration (shift of small world index (clustering coefficient/path length) towards less random topology) after active but not sham tACS is expected.

Change in spectral source space resting-state MEG (relative power)Immediately before and after intervention

Change in relative power will be used, expecting an increase in relative power in higher alpha, beta and gamma bands and decrease in relative power in theta band after active but not sham tACS.

Change in spectral source space resting-state MEG (posterior peak frequency)Immediately before and after intervention

Change in posterior peak frequency will be used, expecting an increase in posterior peak frequency after active but not sham tACS.

Change in source space resting-state MEG network structure (MST variables)Immediately before and after intervention

Change in graph theory parameters will be used as a measure of global network structure. Restoration of overall network configuration (expressed by shift of multiple Minimum spanning tree (MST) parameters towards healthy state, e.g. stronger hierarchy) after active but not sham tACS is expected.

Change in source space resting-state MEG network structure (modulatory index, degree and eigenvector centrality)Immediately before and after intervention

Change in graph theory parameters will be used as a measure of mesoscale network structure (modularory measures) and nodal characteristics (degree and eigenvector centrality). Restoration of hub disruption (stronger modularity index, increase in degree and eigenvector centrality) of precuneus-posterior cingulate and medial temporal lobe after active but not sham tACS is expected.

Change in functional connectivity source space resting-state MEG (AEC-c)Immediately before and after intervention

Change in corrected amplitude envelope correlation (AEC-c) will be used, expecting an increase in AEC-c in higher alpha, beta and gamma bands after active but not sham tACS.

Trial Locations

Locations (1)

Amsterdam UMC, The Netherlands

🇳🇱

Amsterdam, Noord-Holland, Netherlands

© Copyright 2025. All Rights Reserved by MedPath